Atossa Genetics (ATOS) Earns News Sentiment Rating of 0.14

Press coverage about Atossa Genetics (NASDAQ:ATOS) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Atossa Genetics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 49.0622921655418 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, Maxim Group started coverage on Atossa Genetics in a report on Friday, January 26th. They issued a “buy” rating and a $2.00 price objective on the stock.

Atossa Genetics (NASDAQ:ATOS) traded down $0.03 on Friday, hitting $0.58. The stock had a trading volume of 5,285,204 shares, compared to its average volume of 8,349,896. Atossa Genetics has a fifty-two week low of $0.22 and a fifty-two week high of $1.68. The stock has a market cap of $16.65, a P/E ratio of -0.25 and a beta of 3.02.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.12. research analysts expect that Atossa Genetics will post -0.84 earnings per share for the current fiscal year.

WARNING: “Atossa Genetics (ATOS) Earns News Sentiment Rating of 0.14” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at

About Atossa Genetics

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit